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Abstract
Aims/hypothesis This study is a 19 year observational
follow-up of a pragmatic open multicentre cluster-
randomised controlled trial of 6 years of structured personal
diabetes care starting from diagnosis.
Methods A total of 1,381 patients aged ≥40 years and newly
diagnosed with type 2 diabetes were followed up in national
registries for 19 years. Clinical follow-upwas at 6 and 14 years
after diabetes diagnosis. The original 6 year intervention in-
cluded regular follow-up and individualised goal setting, sup-
ported by prompting of doctors, clinical guidelines, feedback
and continuing medical education (ClinicalTrials.gov
NCT01074762). The registry-based endpoints were: inci-
dence of any diabetes-related endpoint; diabetes-related death;
all-cause mortality; myocardial infarction (MI); stroke; pe-
ripheral vascular disease; and microvascular disease.
Results At 14 year clinical follow-up, group differences in
risk factors from the 6 year follow-up had levelled out,
although the prevalence of (micro)albuminuria and level of
triacylglycerols were lower in the intervention group.
During 19 years of registry-based monitoring, all-cause
mortality was not different between the intervention and
comparison groups (58.9 vs 62.3 events per 1,000 patient-
years, respectively; for structured personal care, HR 0.94,
95% CI 0.83, 1.08, p=0.40), but a lower risk emerged for
fatal and non-fatal MI (27.3 vs 33.5, HR 0.81, 95% CI 0.68,
0.98, p=0.030) and any diabetes-related endpoint (69.5 vs
82.1, HR 0.83, 95% CI 0.72, 0.97, p=0.016). These differ-
ences persisted after extensive multivariable adjustment.
Conclusions/interpretation In concert with features such as
prompting, feedback, clinical guidelines and continuing
medical education, individualisation of goal setting and drug
treatment may safely be applied to treat patients newly
diagnosed with type 2 diabetes to lower the risk of diabetes
complications.
Keywords Any diabetes-related endpoint . Chronic care
model . Mortality . Multifactorial intervention . Myocardial
infarction . Stroke . Type 2 diabetes
Abbreviations
ADDITION Anglo-Danish-Dutch Study of Intensive
Treatment in People with Screen-Detected
Diabetes in Primary Care
DCGP Diabetes Care in General Practice
GEE Generalised estimating equations
IQR Interquartile range
MI Myocardial infarction
UKPDS UK Prospective Diabetes Study
Introduction
Strict control of blood glucose [1, 2], BP [3, 4] or lipids [5]
lowers the risk of diabetes complications, and a long-term
legacy effect of intervention started at diabetes diagnosis has
been proposed [6]. Although assessments of the quality of
diabetes care continue to show suboptimal management [7,
8], the benefit of pursuing intensive glucose control in all
patients to reduce cardiovascular disease has been ques-
tioned [9–12]. In response to this, the European Association
for the Study of Diabetes (EASD) and the ADA, in a joint
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position statement, have recommended individualising both
treatment goals and choice of pharmacological intervention
in the management of hyperglycaemia [13]. The application
of evidence-based but individualised treatment schemes in
daily clinical practice may be tested through multifactorial
interventions, targeting health professionals, which have
been shown to improve process measures and risk factors
in primary care [14]. The effects of such complex interven-
tions on cardiovascular and microvascular outcomes are,
however, largely unknown.
The Diabetes Care in General Practice (DCGP) study [15]
was a randomised controlled 6 year trial to assess the effect on
mortality and morbidity of structured personal care compared
with routine care in a population-based sample of patients
newly diagnosed with clinical type 2 diabetes. This 19 year
follow-up of the DCGP study assessed the long-term effec-
tiveness of 6 years of structured personal diabetes care that was
started at diagnosis in primary care. Outcomes were mortality
as well as cardiovascular and microvascular complications.
Methods
Study design The DCGP was a pragmatic open cluster-
randomised controlled trial (ClinicalTrials.gov NCT01074762)
[15]. Of 1,902 general practitioners invited to participate
in 1988, 474 (24.9%) volunteered (Fig. 1). Their practices
were allocated, by random numbers, to give patients either
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structured personal care or routine care. A detailed description
of the study design has been reported previously [15]. The
study was approved by the research ethics committee of
Copenhagen and Frederiksberg and informed consent was
given by all patients.
Patients The doctors were to include all of those on their
practice list who were aged 40 or older and newly diagnosed
with diabetes between 1 March 1989 and 28 February 1991.
In the third year, 71 doctors in the structured-personal-care
group on invitation volunteered to recruit patients for a further
year (Fig. 1). These patients received the same intervention as
the other patients in the structured-care group.
Following recruitment, diagnosis was confirmed by a
single fasting whole-blood/plasma glucose concentration
≥7.0/8.0 mmol/l, measured at a major laboratory. Patients
who were diagnosed during hospitalisation were also con-
sidered for inclusion. The protocol-based exclusion crite-
ria were life-threatening somatic disease, severe mental
illness or unwillingness to participate. For the present
analyses, we excluded patients whose diagnosis was not
confirmed at a major laboratory within 500 days of diag-
nosis [15]. Of 1,381 patients in the final study population,
1,369 (99.1%) were of Western European descent. Based
on onset of insulin treatment, approximately 97.5% of the
patients were considered to have type 2 diabetes.
Intervention In Denmark, routine care for standard type 2
diabetes is usually managed in primary care, with costs covered
by the free tax-based health insurance system. In the interven-
tion group, follow-up every 3 months and annual screening for
diabetes complications were supported by sending a question-
naire to the general practitioner 1 month before the next
expected consultation [15]. The general practitioner was
requested to define, together with the patient, the best possible
goals, within three predefined categories of ‘good’, ‘acceptable’
and ‘poor’ control, for important risk factors, with emphasis on
glycaemic control (Table 1). At each quarterly consultation, the
general practitioner was asked to compare the achievements
with the goal and consider changing either goal or treatment
accordingly. In overweight patients, the general practitioner was
prompted to get agreement on a small realistic weight reduction,
record it and follow up accordingly. However, participants were
not required to target a specific relative body weight.
The general practitioners were introduced to possible sol-
utions to therapeutic problems through six annual half-day
seminars, annual descriptive feedback reports on individual
patients, and folders and leaflets for doctors and patients.
Generally, the importance of diet was stressed and doctors
were recommended to postpone, if possible, the start of
glucose-lowering drugs until at least 3 months after diabetes
diagnosis to observe the effect of any weight loss. It was
suggested that the general practitioners recommend increased
physical exercise and simple dietary rules: to increase complex
carbohydrate to at least 50% of the diet and, in particular, to
increase water-soluble fibre; to reduce fat content to a maxi-
mum of 30%; to reduce alcohol intake; and to eat five or six
meals a day. In cases of persistent hyperglycaemia, metformin
was recommended for patients who were overweight by clin-
ical judgment, and glipizide or glibenclamide was suggested
for patients of normal weight. In patients aged >70 years,
tolbutamide was recommended. If the goal for blood glucose
was not met, a combination of metformin and a sulfonylurea
was suggested as the last step before starting insulin. To treat
hypertension, ACE inhibitors or β blockers were recommen-
ded for most patients, but furosemide (frusemide) was pre-
ferred for patients with heart failure, and thiazides for patients
aged >70 years. Lipid-lowering drugs were recommended for
diet-resistant dyslipidaemia. No patient-specific advice on
treatment was given to doctors, who were allowed to deviate
from the recommendations in an effort to individualise treat-
ment. The patients were never approached by the study centre.
Doctors in the routine-care group were free to choose any
treatment and change it over time [15]. The study coordi-
nating centre did not contact routine-care practices during
the trial period after inclusion had stopped. On 26 Septem-
ber 1995, the intervention was terminated. No further at-
tempt was made to maintain patients in randomised groups
or to influence their therapy.
Table 1 Treatment goals for patients in the structured-personal-care
group during the trial period 1989–1995
Variable Good
controla
Acceptable
controlb
Poor
controlc
Fasting blood glucose (mmol/l)d ≤7.0 ≤8.0 >8.0
Non-fasting blood glucose (mmol/l)d ≤9.0 ≤11.0 >11.0
HbA1c (%)
e ≤7.0 ≤8.5 >8.5
Diastolic BP (mmHg) ≤90 ≤100 >100
Total cholesterol (mmol/l) ≤6.0 ≤7.0 >7.0
Fasting triacylglycerols (mmol/l) ≤2.0 ≤5.0 >5.0
General practitioners were instructed as follows. The aim is normalisation
of blood glucose, BP, lipids and possibly weight. For some patients, it will
be impossible or even inappropriate to try to achieve the ideal goal, but
prolonged symptoms of hyperglycaemia or hypoglycaemia must not be
accepted for any patient. From an overall therapeutic point of view, the
general practitioner can choose to aim at the treatment goals in one of the
three categories. The choice of category is primarily based on HbA1c
a Normalisation of metabolism; this ideal demand is particularly relevant
in young and middle-aged patients and in well-motivated older patients
b Acceptable metabolic regulation; this applies to some older patients and
patients who are difficult to treat and/or difficult to motivate for treatment
c Freedom from symptoms; this category is intended to be chosen when
the course of treatment has shown that any goal other than freedom
from hyperglycaemic symptoms is beyond reach
d Capillary whole-blood glucose
e Reference range 5.4–7.4%
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Registry-based monitoring over 19 years Everyone living
in Denmark is registered in the Danish Civil Registration
System with a permanent and unique personal identification
number, which enables linkage between study populations
and all national registries [16]. In the present study, the vital
and emigration statuses of all patients were certified through
this system, and surviving patients were censored on 31
December 2008. For one patient the vital status could not
be assessed because this person had emigrated in 1992. The
Danish Register of Causes of Death contains, among other
things, information about underlying and possible contribu-
tory causes of death [17]. In four cases the cause of death
was not recorded in this registry. The Danish National
Patient Register includes information on almost all contacts
with hospitals in Denmark (e.g. discharge diagnose[s] and
surgical procedures performed) [18]. These two registries
provided information on deaths or hospital admissions for
relevant conditions (see electronic supplementary material
[ESM] Table 1).
Clinical follow-up examinations 6 and 14 years after diag-
nosis Approximately 6 and 14 years after diabetes diagno-
sis, on 26 September 1995 and 31 October 2003, the general
practitioners of all surviving patients were asked to do a
follow-up examination (Fig. 1). The doctors recorded the
following information: body weight, BP, drug treatment,
severe hypoglycaemic events, number of consultations the
preceding year and if the patient had ever been treated at a
diabetes clinic. In questionnaires, patients gave information
about smoking habits and physical activity in their leisure
time. Fasting blood samples were collected at diagnosis and
at the follow-up examinations and were analysed at Odense
University Hospital; freshly voided morning urine samples
were analysed at Århus University Hospital. Throughout the
study, the fraction of HbA1c was determined by the same
ion-exchange HPLC protocol. The reference interval was
calculated after analysis of samples from 100 blood donors
(age 20–80 years, 33 men, 67 women) to be 5.4–7.4%
(mean±2 SD). Quality assurance was obtained with commer-
cial control preparations from BioRad. The means of low- and
high-control samples were 6.7% (0.31%) and 10.4% (0.63%),
respectively, resulting in CVs of 4.6% and 6.0% (CV=SD×
100/mean). This method was later compared with a newer
HPLC method (using an automated HbA1c analyser, Tosoh
G7), which was aligned with the DCCT using calibrators
from the European Reference Laboratory for Glycated
Haemoglobin (ERL). The association between the two
methods is approximately linear (R2 0.9049, n=484,
p<0.0001), and is expressed by the following algorithm:
current method=0.268+1.072×DCCT-aligned method.
Although it is impossible to convert individual measure-
ments made using the current method to the newer meth-
od, the reference range of the current method (5.4–7.4%)
may, with caution, be converted to 4.8–6.7% (29–
50 mmol/mol), which corresponds approximately to
DCCT values. A description of other variables and defi-
nitions has previously been published [15].
The 6 and 14 year clinical follow-up examinations were
done for 970 (93.4%) and 539 (92.1%) of 1,039 and 585
surviving patients, respectively (Fig. 1). Because patients
moved or new doctors joined or took over a practice, 147
new doctors joined the study during the first 6 years and a
further 114 new doctors volunteered for the 14 year follow-
up. The clustering of patients according to general practi-
tioners and the number of patients who moved to a doctor
outside the original randomisation arm throughout the trial
are given in ESM Tables 2 and 3.
Statistical analysis For clinical, biochemical, behavioural
and process variables the randomisation arms were compared
for the patients who completed the 6 and 14 year follow-up
with the p values of the corresponding regression coefficients
from a multivariate generalised linear model in which the
effect of randomisation group was adjusted for age, sex and
diabetes duration: ordinary linear regression for continuous
variables, logistic regression for binary variables and Poisson
regression for count variables with loge(diabetes duration) as
offset. Clustering with general practitioners was accounted for
by the use of generalised estimating equations (GEE).
The outcomes used in the registry-based follow-up were
made with reference to those in the UK Prospective Diabe-
tes Study (UKPDS) [6]: any diabetes-related endpoint,
diabetes-related deaths, all-cause mortality, myocardial in-
farction (MI), stroke, peripheral vascular disease and micro-
vascular disease (ESM Table 1). Length of time from
diagnosis to death or incident outcomes was analysed with
logrank tests and Cox regression models. The proportional
hazard assumption was tested by adding the interactions of
each of the independent variables in the model with the
natural logarithm of time to event to the model. A joint test
of these interactions tested the assumption. When one or
more of the interactions were significant, the hazard func-
tion was estimated separately within strata of the
corresponding covariates. A sandwich estimator for the
variance was used to account for clustering [19].
All variables and endpoints were analysed with SAS v9.2
(SAS Institute Inc., Cary, NC, USA) according to the
intention-to-treat principle. The level of statistical signifi-
cance was p<5%.
Results
At diabetes diagnosis, median age (interquartile range
[IQR]) for the 1,381 patients was 65.4 (55.7–73.6) years
and male:female ratio was 1.13 (733:648). The 6 and 14 year
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clinical follow-up examinations were attended by a similar
proportion of surviving intervention and routine-care
patients (94.2% [549/583] vs 92.3% [421/456], p=0.24,
and 91.9% [307/334] vs 92.4% [232/251], p=0.82, respec-
tively, χ2 test, Fig. 1).
At the end of intervention, the structured-personal-care
group had significantly lower levels of HbA1c (8.4% vs
9.0%, reference range 5.4–7.4%, p<0.0001), systolic BP
(145 vs 150 mmHg, p=0.003) and total cholesterol (6.0 vs
6.1 mmol/l, p=0.033) than the routine-care group (Table 2).
At 14 year clinical follow-up, group differences had levelled
out, though some of the measures suggest a lasting inter-
vention effect, with a lower level of triacylglycerols, a lower
prevalence of (micro)albuminuria, and fewer referrals to a
diabetes clinic.
At the end of the intervention, metformin was more widely
used in the intervention group (24 vs 15%, p<0.001) than in
the routine-care group, the only significant group difference in
use of drugs observed [15]. In the 14 year follow-up, the two
groups received similar but more intensive drug treatment
(ESM Table 4).
During 19 years of registry-based monitoring, all seven
predefined outcomes were experienced by a lower propor-
tion of patients receiving structured personal care compared
with patients receiving routine care (Table 3, Fig. 2). Group
differences were, however, only statistically significant for
any diabetes-related endpoint (HR for structured care 0.83,
95% CI 0.72, 0.97, p=0.016) and fatal or non-fatal MI (HR
0.81, 95% CI 0.68, 0.98, p=0.030). These differences per-
sisted after extensive multivariate adjustment: HR 0.80,
95% CI 0.69, 0.92, p=0.003 and HR 0.81, 95% CI 0.67,
0.99, p=0.039, respectively. Survival was not statistically
significantly associated with the intervention (HR 0.94, 95%
CI 0.82, 1.08, p=0.40, with multivariate adjustment, Table 3
and Fig. 2). In the period after the intervention was termi-
nated, there was a non-significant tendency towards lower
incidence rates for structured care for most outcomes, and
this propensity was most pronounced for stroke and any
diabetes-related endpoint (Fig. 2, Table 3). Apart from pe-
ripheral vascular disease and microvascular disease the pro-
portion of patients with an outcome was relatively high. For
any diabetes-related endpoint the number (%) of patients in
the intervention and control groups were 405 (66.3%) and
366 (73.4%). For MI the corresponding figures were 219
(31.5%) and 210 (37.3%), respectively.
Discussion
This long-term follow-up of the DCGP randomised trial of
structured personal diabetes care was analysed as an obser-
vational study with extensive adjustments for clustering and
confounders. During 19 years of monitoring, a statistically
significantly reduced risk for MI and any diabetes-related
endpoint emerged for patients in the intervention arm. No
effect was shown on peripheral vascular disease and micro-
vascular outcomes, possibly because our study was under-
powered to detect group differences for these events, which
were rare compared with the other outcomes in this study. In
comparison with most trials from outpatient clinics [1–4,
20], our study population was small and attrition was high,
mainly due to the high mortality in our ageing population-
based patient sample. On one hand, the many outcomes
caused by the high average age at diagnosis (65 years)
endowed the study with statistical strength to analyse group
differences in mortality and incidences of cardiovascular
outcomes. On the other hand, in elderly patients these out-
comes in particular are expected to have causes unrelated to
diabetes, and the final results of this study appear as a trade-
off between these underlying preconditions.
When the intervention was terminated, the between-
group differences in fasting plasma glucose, HbA1c, total
cholesterol and BP were relatively small compared with the
UKPDS glucose and hypertension trials [1, 3]. After a
further 8 years, these differences in risk factors had levelled
out as most risk factors improved in both treatment groups
and treatment intensity had increased (Table 2, ESM Ta-
ble 4). The improvements in (micro)albuminuria and fasting
triacylglycerols at 14 year follow-up, however, indicates a
lasting intervention effect on surrogate outcomes beyond
that seen in UKPDS [6]. All things considered, these find-
ings add to the evidence for a legacy intervention effect in
type 2 diabetes on long-term development of complications,
and extend them to the primary healthcare setting. They also
suggest that improved outcomes may be attainable within
the framework of a complex intervention with individual-
ised treatment.
Previous research Overall, the effectiveness of different
solitary quality-improvement strategies for glycaemic con-
trol in type 2 diabetes is modest. We incorporated regular
follow-up, prompting of doctors, feedback on individual
patients, clinical guidelines and continuing medical educa-
tion for doctors in our multifaceted intervention because all
these elements seem to be effective [14, 21–23]. Later, all of
these aspects of chronic care were included in the chronic
care model [24–26]. On top of this, we added individualised
goal setting [27, 28]. In complex interventions the effect
cannot easily be ascribed to single elements, but it is likely
that the improvements in both risk factors and endpoints can
be explained, at least partly, by the combined effect of small
changes in process and lifestyle measures, which we were
unable to pick up with our relatively simple data collection
instruments (Table 2). The intervention probably had too
little focus on smoking cessation, increased physical activity
and prescription of lipid-lowering drugs (Table 2; ESM
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Table 4), and, in general, the patients might have benefitted
from more intensive theory-based patient education and
support [29].
In blood glucose trials testing intensive multipharmaco-
logical treatment to target, adverse weight gain is common
[1, 9–11, 20]. In the DCGP study, in which it was recom-
mended that treatment goals for risk factors including
weight be negotiated by the doctor and patient, an average
weight loss was maintained for 14 years in both groups. In
the intervention group, doctors had been asked not to start
drug treatment before the patients had experienced the
effects of their own efforts to shape a new lifestyle [15,
30]. Other lifestyle interventions have been shown to reduce
the use of medication for diabetes considerably [31], and
diet may be the most important component of such inter-
ventions [32].
Patients’ absolute risk of developing a cardiovascular
outcome was greater than in other diabetes trials [1, 3, 6,
9–11, 33, 34] (Table 3). For MI defined as in the present
analyses, a meta-analysis [12] of these trials [1, 10, 11, 34]
found event rates of 13.3 and 14.7 per 1,000 patient-years in
intervention and control groups, respectively, and HR 0.90
(95% CI 0.82, 0.99). In the DCGP study the corresponding
figures were event rates of 27.3 and 33.5 per 1,000 patient-
years and HR 0.81 (95% CI 0.67, 0.99) (Table 3). Thus, the
incidence of MI in DCGP was twice that of major cardio-
vascular outcome studies of intensive glucose control in
type 2 diabetes, and the absolute risk reduction for intensive
care was four times greater. Relatively old patients may be
more compliant than younger patients [35], and the
personalised care may be particularly well taken up by
elderly patients, which could contribute to the explanation
of our results.
Further strengths and weaknesses The study was originally
conducted and reported as a cluster-randomised trial
[15]. The present analyses are not described in the
protocol, and are therefore interpreted as observational
and reported in accordance with the Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) recommendations [36], with adjustment for
confounders and clustering.
Our main results rest on long-term follow-up in major
Danish registries. The vital status and cause of death could
be confirmed for 99.9% and 99.7% of study participants,
respectively. The Danish Register of Causes of Death has
covered the entire population of Denmark since 1875 [17],
and the Danish National Patient Registry has covered 99.4%
of discharges from Danish hospitals since 1977 [37]. From
1995 onwards the registry has also included emergency
room and outpatient clinic visits, but the registry has only
covered all contacts with hospitals in Denmark since 2007,
primarily because registrations from the few and small pri-
vate specialised hospitals were missing [18]. However, these
hospitals are not supposed to be contributors of information
about the outcomes in this study. Both registries have
changed registration and coding practices on several occa-
sions, and the concepts and definitions of diseases have
changed; new diagnostic criteria for MI were introduced in
2000, for example. In the nationwide DCGP study these
time-dependent changes in registration are unlikely to cause
differential misclassification according to treatment alloca-
tion. The validity has not been established for all the
registry-based diagnoses in Table 3, but for MI as primary
diagnosis or underlying cause of death the predictive value
was 93.6% and the sensitivity was 77.6% in comparison
with definite or possible MI as diagnosed in the Monitoring
Trends and Determinants in Cardiovascular Disease
(MONICA) Project in Denmark [38]. In a small retrospec-
tive audit of patient records, the predictive value of the
stroke diagnosis in the Danish National Patient Register
was 81–86% [39].
While our registry data in Table 3 are relatively strong,
our results in Table 2 from the clinical follow-up of surviv-
ing patients must be interpreted in view of the slightly
unequal attrition across randomisation groups. Similarly,
even for those re-examined at 6 and 14 year follow-up, data
may be missing differentially according to outcomes. Esti-
mations of biochemical variables, however, were centralised
and quality controlled.
In the registry-based follow-up, detailed information en-
abled us to make extensive adjustments for a wide spectrum
of clinically relevant confounding factors, which, for most
Fig. 2 Kaplan–Meier plots showing the proportion of patients without
four selected outcomes since diabetes diagnosis: (a) any diabetes-
related endpoint (p=0.010); (b) all-cause mortality (p=0.38); (c) MI
(p=0.033); and (d) stroke (p=0.16). Black line, structured-personal-
care group; grey line, routine-care group. p values are from unadjusted
logrank tests
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outcomes, did not change the risk estimates decisively. This
may also be because the indirect randomisation was suc-
cessful (Table 2), though patient inclusion was done without
concealing treatment allocation.
It is likely that the results of the DCGP study can be
generalised to the general population of patients with type 2
diabetes because: (1) the study was conducted in general
practice, where most patients with type 2 diabetes are trea-
ted; (2) the study sample was population-based; (3) patients
were included with no upper age limit, and the present
results from older patients with higher baseline cardiovas-
cular risk may even widen the generalisability of findings
from other studies; (4) the elements of the intervention
resemble standard procedures in general practice; and (5) a
relatively high number of general practices participated. The
fact that general practitioners volunteered for the study may
have increased the treatment quality in the routine-care
group [40], in which doctors were supposed to do their
best and where risk factors were better controlled than
in, for example, the conventional treatment group in
UKPDS [1]. Between 1988 and 1996 all Danish general
practitioners received five diabetes guidelines by post
[41–43], which may have decreased the size of the
effect of the intervention. The same may be said about
the considerable movement of patients between practices
during the first 14 years after diagnosis (ESM Table 3).
During the 6 years of intervention, however, a doctor
who took over an intervention patient was instructed as
for any other intervention doctor.
Clinical implications and perspectives The Steno-2 study
was a demonstration trial from secondary care showing
convincing risk reductions by multifaceted intervention to
achieve strict targets directed at a group at high risk of death
and complications [20, 44]. In the Anglo-Danish-Dutch
Study of Intensive Treatment In People with Screen-
Detected Diabetes in Primary Care (ADDITION) study
from general practice a similar target-driven intensive-
treatment algorithm applied to patients with type 2 diabetes
detected by screening did not reduce cardiovascular
events, possibly because the general improvements in
diabetes care lowered the achievable differences in treat-
ment between trial arms [45].
The DCGP intervention was applied in 1989–1995,
before a more intensive treatment regimen addressing
blood glucose, BP and dyslipidaemia was implemented.
Although a healthy survivor effect may have contribut-
ed, the effect of these new guidelines on both risk
factor level (Table 2) and drug treatment (ESM Table 4)
at the 14 year follow-up in 2003–2005 seems evident in
both treatment arms, which makes the present analyses
well suited for estimating the effect of an early intervention
starting at diagnosis.
In concert with the 10-year follow-up of the UKPDS
study [6] and the non-significant improvements in outcome
in the ADDITION study [45], the DCGP study indicates
long-term clinical benefits of early improvement in the
metabolic management of older patients with less well-
controlled type 2 diabetes.
In agreement with the recommendations of contemporary
clinical guidelines [13], the treatment efforts in the DCGP
study were individualised, but the clinical guidelines and
treatment targets used in the DCGP study should be updated
to contemporary standards. Nowadays, patient involvement
may be facilitated by a computerised decision aid that
includes the calculated risk of complications and many
relevant patient characteristics, such as age, sex, social
background and comorbidity. In this way the emerging
need for personalised treatment in type 2 diabetes, based
on both scientific evidence and patient preferences [46],
may be met and even better results obtained than in the
present study.
Conclusions
In general practice, 6 years of structured personal care
starting from diabetes diagnosis was associated with a re-
duced risk of MI and any diabetes-related endpoint during
19 years of registry-based monitoring, but survival did not
differ between treatment groups. This took place without
any overall increase in medication and occurrence of hypo-
glycaemia, and an average weight loss was sustained. This
study is relevant to daily clinical practice because the ele-
ments of the complex multifaceted DCGP intervention are
relatively easy to implement, and because the study partic-
ipants were sampled from the general population, with no
upper age limit, and were treated in general practice, as is
the case for most people with type 2 diabetes. The results
indicate that individualisation of both goal setting and
choice of pharmacological interventions may be safely in-
cluded in a multifaceted contemporary treatment regimen.
Finally, the results lend support to the assumption that
enhanced quality of early diabetes treatment, starting at
diabetes diagnosis, is important for lowering the long-term
risk of diabetes complications.
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